177Lu-LNC1010 is a new radiolabeled drug targeting somatostatin receptors (sstr), developed by the company Yantai LNC (Lannacheng) Biotechnology, Singapore, a subsidiary of DongCheng Pharmaceutical. Patients are selected on the basis of the diagnostic companion molecule 68Ga-DOTATATE. A Phase I trial was initiated in June 2022 at the First Affiliated Hospital of Xiamen University, China.
Target/Mechanism: Somatostatin receptors
Radiation Type: beta electrons (β–)